|
16 November, 2012
|
ICON Announces Publication of EGM Circular in Respect of Proposed Conversion to Direct Listing of its Shares on NASDAQ
|
|
|
01 November, 2012
|
ICON Reports Q3 Revenue of $286 Million, EPS of 29c and Net New Business of $450 Million. (NASDAQ: ICLR) (ISIN:IE0005711209)
|
|
|
05 September, 2012
|
ICON Forms Strategic Partnership with University College Dublin
|
|
|
24 July, 2012
|
ICON Reports second quarter 2012 revenue up 19% to $277 million and non-GAAP EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209)
|
|
|
20 July, 2012
|
ICON Shareholders Vote in Favour of All Resolutions at Its Annual General Meeting
|
|
|
12 June, 2012
|
ICON Announces Peter Gray to Retire from ICON Board of Directors
|
|
|
24 April, 2012
|
ICON reports a 10% increase in first quarter 2012 revenue to $252m, up 10% year on year, EPS of 15 cents, net new business awards of $385 million and a B:B of 1.5. (NASDAQ:ICLR) (ISIN:IE0005711209)
|
|
|
05 March, 2012
|
ICON Selected by Roche for Technology Partnership
|
|
|
28 February, 2012
|
ICON Acquires PriceSpective
|
|
|
16 February, 2012
|
ICON reports fourth quarter 2011 revenue of $243m, up 5% year on year, and EPS of $0.07. Backlog increases 19%. (NASDAQ:ICLR) (ISIN:IE0005711209)
|
|
|
15 February, 2012
|
ICON Completes Acquisition of BeijingWits Medical Consulting Ltd
|
|
|
09 January, 2012
|
ICON Selected by Shire plc's Specialty Pharmaceuticals division as Global Strategic Partner for Clinical Research and Central Laboratory Services
|
|
|
27 December, 2011
|
ICON Announces Dr. Anthony Murphy To Retire From Board of Directors
|
|
|
12 December, 2011
|
ICON Acquires BeijingWits Medical Consulting Ltd
|
|
|
22 November, 2011
|
ICON plc: Commencement of Share Repurchase Programme
|
|
|
01 November, 2011
|
ICON Names New Global Head of Clinical Research Services
|
|
|
27 October, 2011
|
ICON Reports Q3 revenue growth of 7% to $241 million and net new business of $431 million. (NASDAQ:ICLR) (ISIN:IE0005711209)
|
|
|
07 September, 2011
|
ICON Announces Peter Gray To Retire As CEO
|
|
|
30 August, 2011
|
ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb
|
|
|
20 July, 2011
|
ICON Reports Second Quarter 2011 Net New Business of $310 million, Revenue of $233 million and EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209)
|
|
